March 31, 2017 / 11:13 AM / 8 months ago

BRIEF-Can-Fite sees FY 2019 sales $1.4 billion

March 31 (Reuters) - Can Fite Biopharma Ltd:

* Can Fite reports 2016 financial results & provides clinical update

* Sees FY 2019 sales $1.4 billion

* Can Fite Biopharma Ltd - Can Fite expects to be ready to commence its pivotal phase III acrobat trial of piclidenoson in Q2 of 2017

* Can Fite Biopharma Ltd - Psoriasis market is forecast to be $8.9 billion in 2018 and otezla® sales are estimated to be $2.35 billion by 2020

* Can Fite Biopharma Ltd - liver cancer drugs are expected to generate $1.4 billion in sales in 2019

* Can Fite Biopharma Ltd - by 2025, addressable pharmaceutical market for NASH is estimated to reach $35-40 billion Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below